

Case NOTAR-032US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: **Fabrizio Poccia et al.**)
Serial No.: **Unknown**) Art Unit: **Unknown**
Filing Date: **Herewith**) Examiner: **Unknown**
For: **METHOD AND DIAGNOSTIC**)
TESTS BASED ON FLOW)
CYTOMETRIC ANALYSIS OF)
ANTIGEN-SPECIFIC T)
LYMPHOCYTES)

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. SECTION 1.97

Mail Stop Amendment
Assistant Commissioner for Patents
Post Office Box 1450
Alexandria, Virginia 22313-1450

Dear Sir/Madam:

Pursuant to 37 C.F.R. § 1.97, the following Information Disclosure Statement is submitted as listed on forms PTO/SB/08A and PTO/SB/08B enclosed herewith in duplicate. A copy of the non-patent literature and foreign disclosure documents are attached hereto for the Examiner's review.

No representation is made that the references disclosed herein legally constitute prior art, or that more relevant references are not available. The disclosure document enclosed herewith and listed on the attached forms PTO/SB/08A and PTO/SB/08B are printed in the English language and/or accompanied by an Abstract published in the English language.

The references listed herein, when taken alone or in combination, are not believed to disclose nor make obvious the invention as claimed in the subject application.

IAP20 Rec'd PCT/PTO 06 FEB 2006


As this Information Disclosure Statement is being submitted before the stipulated three months from the filing date of the application and/or before the mailing of a first Office Action, it is believed that no fee is required.

If a fee is required, please charge Account Number 19-4330.

Respectfully submitted,

Dated: February 6, 2006

By:



Kit M. Stetina, Esq.
Registration No. 29;445
STETINA BRUNDA GARRED & BRUCKER
75 Enterprise, Suite 250
Aliso Viejo, CA 92656
(949) 855-1246

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.~~

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	Unknown
Filing Date	10/15/2015
First Named Inventor	Herewith
Art Unit	Fabrizio Poccia
Examiner Name	Unknown
Attorney Docket Number	Unknown
	NOTAR-032US

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 2004/024756 A2	03-25-2004	GSF-Forschungszentrum Fur Umwelt		
		EP 1 398 380 A1	03-17-2004	GSF-Forschungszentrum		
		WO 2004/067032 A2	09-12-2004	University of Massachusetts Medical		
		WO 03/015702 A2	02-27-2003	The General Hospital Corporation		

**Examiner
Signature**

Date Considered

<p> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by Translation is attached. </p>	<p> Considered </p>
---	---------------------

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number

Unknown **10/567541**

Filing Date

Herewith

First Named Inventor

Fabrizio Puccio

Art Unit

Unknown

Examiner Name

Unknown

Attorney Docket Number

NOTAR-032US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		JOHN WILEY & SONS, INC.; "Detection of Intracellular Cytokines by Flow Cytometry"; Current Protocols in Immunology; 2002; pgs. 6.24.1 - 6.24.7	
		MASSIMO AMICOSANTE ET AL.; "Computer-Based Design of an HLA-Haplotype and HIV-Clade Independent Cytotoxic T-Lymphocyte Assay for Monitoring HIV-Specific Immunity"; Molecular Medicine; 2002; pgs. 798-807	
		HOLDEN T. MAECKER ET AL.; "Use of Overlapping Peptide Mixtures as Antigens for Cytokine Flow Cytometry"; Journal of Immunological Methods; 2001; pg 27-40	
		MICHAEL R. BETTS ET AL.; "Monitoring HIV-Specific CD8 + T Cell Responses by Intracellular Cytokine Production"; Immunology Letters; 2001; pg. 117-125	
		PHILIP J.R. GOULDER ET AL.; "Rapid Definition of Five Novel HLA-A 3002-Restricted Human Immunodeficiency Virus-Specific Cytotoxic T-Lymphocyte Epitopes by Elispor and Intracellular Cytokine Straining Assays"; Feb. 2001; pg. 1339-1347	
		XU G. YU ET AL.; "Important Contribution of P15 Gag-Specific Responses to the Total Gag-Specific CTL Responses"; Lippincott Williams & Wilkins; 2002; pg. 321-328	
		INGO DREXLER ET AL.; "Identification of Vaccinia Virus Epitope-Specific HLA-A 0201-Restricted T Cells and Comparative Analysis of Smallpox Vaccines"; PNAS; Jan. 2003; pgs. 217-222	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.